Last checked at 3 Jan 2023 09:24
LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Hikma Pharmaceuticals Share News (HIK)
HIK Share
Price
HIK Share
News
HIK Share
Chat
HIK Share
Trades762
HIK
Live RNS
HIK Share
Charts
HIK Level 2
Console
HIK Live
Share Price
HIK Broker
Ratings
HIK Directors
Deals
HIK Financial
Diary
HIK
Fundamentals
HIK Short
Positions
HIK
Media
Hikma Pharmaceuticals Information
Share Price Information for Hikma Pharmaceuticals (HIK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,933.00
Bid:
1,932.00
Ask:
1,933.00
Change:
3.00 (0.16%)
Spread:
1.00 (0.052%)
Open:
1,937.00
High:
1,947.00
Low:
1,916.00
Prev. Close:
1,930.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Hikma Pharmaceuticals hiked by court colchicine ruling
Mon, 12th Jan 2015 08:08
A US court has given Hikma Pharmaceuticals permission to distribute its colchicine gout treatment, turning down rival Takeda Pharmaceuticals in its appeal for an injunction against the distribution of the drugs.The injunction, which was granted to Takeda on 9 October 2014, has been vacated following the District of Delaware's decision.Hikma, which is eyeing a potential promotion into the FTSE 100 this year, said it will now prepare to distribute its colchicine products, which it will market under the brand name Mitigare. The group will also release a generic version of the drug, used to prevent gout flares in adults."I am very pleased to be launching our colchicine products, demonstrating our success in developing a more differentiated product portfolio for the US market," said chairman Said Darwazah.Sales of colchicine in the US market were about $688m for the year ended August 2014 and broker JP Morgan Cazenove said recently that US colchicine launch upside for the company "could potentially be worth circa £2 per share".
More News
3 Jan 2023 09:03
LONDON MARKET OPEN: Stocks jump in first session of 2023
(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.
Read more3 Jan 2023 07:58
LONDON BRIEFING: Stocks called higher; China factory sector shrinks
(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.
Read more3 Jan 2023 07:46
Hikma launches generic narcolepsy solution in US
(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.
Read more8 Dec 2022 09:48
LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:
Read more6 Dec 2022 10:48
RBC Capital Markets starts Hikma at 'outperform'
(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.
Read more6 Dec 2022 10:26
LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:
Read more15 Nov 2022 12:10
Credit Suisse initiates coverage of Hikma at 'outperform'
(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.
Read more15 Nov 2022 09:58
LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
Read more14 Nov 2022 09:25
LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:
Read more8 Nov 2022 09:39
LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
Read more3 Nov 2022 11:17
Hikma Pharmaceuticals reiterates 2022 guidance as costs widen
(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.
Read more3 Nov 2022 11:08
3 Nov 2022 09:28
Banks, insurance dodge carnage as real estate stocks sink
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .
Read more3 Nov 2022 09:18
LONDON MARKET OPEN: BT results disappoint; pound falls on Fed outlook
(Alliance News) - Stock prices in London opened lower on Thursday, as the pound fell against a strengthening dollar, after the Federal Reserve indicated that US interest rates are likely to reach higher levels than previously thought.
Read more